Alere study shows simple PIGF can accurately quantify pre-eclampsia risk

Alere announced the results of a study, presented at the 20th FIGO World Congress of Obstetrics and Gynecology, which demonstrate that a simple blood test measuring placental growth factor, or PlGF, can help to quantify risk in women when pre-eclampsia is first suspected. The level of PlGF in blood is already known to be an important marker for placental and foetal wellbeing as well as the placenta's ability to sustain the pregnancy. The PELICAN data have demonstrated that PlGF testing before 35 weeks enables physicians to categorise women into low and high risk for disease progression and to adjust clinical management appropriately.